Buyout
Transforming high-quality businesses into global market leaders. We're committed to long-term value creation, actively partnering with management teams to drive performance and sustainable growth.
Sector-driven, growth-focused buyout investments:
- Technology
- Consumer
- Healthcare
- Services
Deep vertical and horizontal technology expertise to create value
Highly-collaborative partnership approach, from our first meeting through to exit
Ambitious, sector-specialised value creation plans
~190
Investment professionals globally
~€45bn+
Invested in buyouts since inception
16%
YoY sales growth across the P5-P7 funds' portfolio
Team
Recent Investments
Related News & Insights
News
31 Jan 2023
Evelyn Partners Group Limited Fourth quarter trading update for the three months ended 31 December 2022
News
24 Jan 2023
Neuraxpharm completes its presence in Benelux by opening an affiliate in Brussels to cover Belgium and Luxembourg
News
18 Jan 2023
Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services
News
16 Dec 2022
HighTide Therapeutics and Quotient Sciences Announce Agreement to Conduct a 14C Human ADME Program for HTD1801
News
6 Dec 2022
Kroll Acquires Appraisal & Valuation Consultants LTD to Create Dedicated Energy Team within the Fixed Asset Advisory Services Practice
News
1 Dec 2022
Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure’s First Clinical Pharmacokinetic Study for EMPLI03
News
22 Nov 2022
Consortium led by Hellman & Friedman and Permira completes acquisition of Zendesk
News
21 Nov 2022
Cambrex to Acquire Snapdragon Chemistry, a Leader in Continuous Flow API Development Services
News
9 Nov 2022
Reorg and FinDox to Combine to Offer Best-In-Class Solutions for the Credit Markets
News
25 Oct 2022